

Local progression-free survival	CA							
	0.90 (0.22-3.73)	TACE+RFA						
	0.78 (0.22-2.71)	0.86 (0.28-2.65)	PBT					
	0.66 (0.18-2.38)	0.73 (0.23-2.33)	0.84 (0.33-2.17)	LA				
	0.57 (0.19-1.67)	0.63 (0.25-1.59)	0.73 (0.39-1.37)	0.86 (0.43-1.74)	RFA			
	0.41 (0.12-1.34)	0.45 (0.16-1.30)	0.53 (0.24-1.17)	0.62 (0.26-1.47)	0.72 (0.44-1.18)	MWA		
	0.22 (0.06-0.77)	0.25 (0.08-0.75)	0.29 (0.12-0.69)	0.34 (0.14-0.85)	0.39 (0.22-0.71)	0.55 (0.25-1.19)	PAI	
	0.21 (0.06-0.68)	0.23 (0.08-0.66)	0.27 (0.12-0.60)	0.32 (0.14-0.75)	0.37 (0.23-0.60)	0.51 (0.26-1.03)	0.94 (0.55-1.60)	PEI

Supplementary Figure 3. League table showing hazard ratios of local progression-free survival for pairwise comparisons between treatments. Comparisons should be read from left to right. HRs (95% confidence intervals [CI]) for comparisons are in the shared cells. PAI, percutaneous acetic acid injections; CA, cryoablation; RFA, radiofrequency ablation; LA, laser ablation; PBT, proton beam therapy; TACE, trans-arterial chemoembolization; MWA, microwave ablation; PEI, percutaneous ethanol injection; HRs, hazard ratios.